Attracting 60,000 Adalimumab Patients Aids Biogen

Biogen’s Total Year-To-Date Biosimilar Sales Top $500m

 
• By Aidan Fry
  
60000
Biogen says around 60,000 patients are now taking its Imraldi adalimumab biosimilar • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products